Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage European companies.

Our current portfolio comprises biotech, medtech and diagnostics companies, all working to develop truly disruptive solutions for high unmet medical needs.

Dezima and Acerta, multi-billion Euro success stories

BioGeneration was co-founder and investor in two of the most successful biotech startups in Europe: Acerta Pharma and Dezima Pharma. Acerta Pharma develops a new drug for the treatment of hematologic malignancies (leukemia) and was sold to AstraZeneca for up to US$ 7 billion. Dezima Pharma is developing a treatment for of a cardiovascular disorder (dyslipidemia) and was sold to Amgen for a deal amount of up to US$ 1.5 billion.

Shaping new life-science ventures

Our varied and complementary experience has been gained from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Mellon Medical secures € 6 million for market introduction

Nijmegen, The Netherlands, 2 October 2017 – Mellon Medical, a Dutch MedTech developer of a platform technology for suturing with one hand, has raised € 6 million to advance its patented ground breaking global innovation in suturing technology. Leading product, the...

Next events

6-8 November 2017, Bio-Europe, Berlin

Edward van Wezel and Oskar Slotboom shall attend Bio-Europe in Berlin.  You can invite us for a one-on-one meeting through the partnering system. More info >

Latest investments

Subscribe to BGV news updates

Join our mailing list to receive the latest news and updates from our team.

Please check your email to complete your subscription.